BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31790437)

  • 21. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis.
    Zhang CH; Xu GL; Jia WD; Ge YS; Li JS; Ma JL; Ren WH
    Int J Cancer; 2012 Jun; 130(11):2685-92. PubMed ID: 21780114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic value of tertiary lymphoid structures in hepatocellular carcinoma: a meta-analysis and systematic review.
    Hu L; Li X; Yang C; Zhou B; Du C; Jiang N
    Front Immunol; 2024; 15():1390938. PubMed ID: 38887293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization.
    Lautem A; Simon F; Hoppe-Lotichius M; Mittler J; Vollmar J; Schad A; Düber C; Galle PR; Otto G; Zimmermann T; Lang H
    Oncol Rep; 2019 Apr; 41(4):2299-2310. PubMed ID: 30720132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
    Fernandez-Sevilla E; Allard MA; Selten J; Golse N; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Adam R
    Liver Transpl; 2017 Apr; 23(4):440-447. PubMed ID: 28187493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis.
    Wang WM; Xu Y; Yang XR; Wang YH; Sun HX; Fan J
    Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):346-55. PubMed ID: 21813381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.
    Zhu GQ; Shi KQ; Yu HJ; He SY; Braddock M; Zhou MT; Chen YP; Zheng MH
    Oncotarget; 2015 Jul; 6(20):18151-61. PubMed ID: 26061709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
    Qi X; Liu L; Wang D; Li H; Su C; Guo X
    Oncotarget; 2015 Nov; 6(34):36838-59. PubMed ID: 26451613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis: prognostic value of survivin in patients with hepatocellular carcinoma.
    Liu JL; Zhang XJ; Zhang Z; Zhang AH; Wang W; Dong JH
    PLoS One; 2013; 8(12):e83350. PubMed ID: 24386184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis.
    Chen C; Ma YH; Zhang YT; Zhang F; Zhou N; Wang X; Liu T; Li YM
    Cytotherapy; 2018 Aug; 20(8):975-989. PubMed ID: 30072299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis.
    Fan JL; Yang YF; Yuan CH; Chen H; Wang FB
    Cell Physiol Biochem; 2015; 37(2):629-40. PubMed ID: 26344495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
    Wu MT; He SY; Chen SL; Li LF; He ZQ; Zhu YY; He X; Chen H
    BMC Cancer; 2019 Jun; 19(1):538. PubMed ID: 31164099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of Anxa2 and Stat3 promote progression of hepatocellular carcinoma and predict poor prognosis.
    Tang L; Liu JX; Zhang ZJ; Xu CZ; Zhang XN; Huang WR; Zhou DH; Wang RR; Chen XD; Xiao MB; Qu LS; Lu CH
    Pathol Res Pract; 2019 Jun; 215(6):152386. PubMed ID: 30935762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
    Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
    BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chu MO; Shen CH; Chang TS; Xu HW; Yen CW; Lu SN; Hung CH
    Sci Rep; 2018 Nov; 8(1):16611. PubMed ID: 30413724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.
    Erridge S; Pucher PH; Markar SR; Malietzis G; Athanasiou T; Darzi A; Sodergren MH; Jiao LR
    Br J Surg; 2017 Oct; 104(11):1433-1442. PubMed ID: 28628947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis.
    Zhang L; Yuan Q; Li M; Chai D; Deng W; Wang W
    BMC Cancer; 2020 Nov; 20(1):1167. PubMed ID: 33256658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.